Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer
Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer
复制标题
DOI：
10.1007/s12282-013-0515-x
复制
发表时间：
2015-09-01
期刊：
影响因子：
4
通讯作者：
Maehara, Yoshihiko
中科院分区：
文献类型：
--
作者：
Hisamatsu, Yuichi;Tokunaga, Eriko;Maehara, Yoshihiko
激素受体（HR）阳性/HER 2阴性乳腺癌患者辅助化疗（CT）的适应症很难确定。转录因子GATA结合蛋白3（加塔-3）和叉头盒蛋白A1（FOXA 1）对乳腺癌的激素应答表型至关重要。本研究旨在探讨加塔-3和FOXA 1的表达是否是HR阳性/HER 2阴性乳腺癌患者预后和预后的预测指标。方法采用免疫组化法检测214例浸润性乳腺癌患者中加塔-3和FOXA 1的表达，并分析其与临床病理特征和预后的关系。3与FOXA 1的表达呈正相关（P < 0.0001）。加塔-3和FOXA 1均与ER（P < 0.0001）和PR表达（分别为P = 0.0001和P = 0.0009）呈正相关，与细胞核分级（分别为P = 0.0002和P = 0.0018）和Ki 67指数（分别为P = 0.0052和P = 0.0049）呈负相关。加塔-3和FOXA 1的表达与较好的预后相关。FOXA 1是HR阳性/HER 2阴性乳腺癌的独立有利预后标志物。HR阳性/HER 2阴性乳腺癌患者中FOXA 1高表达者单独接受辅助性激素治疗（HT）和接受CT + HT的患者无病生存率相似。结论加塔-3和FOXA 1与HR阳性/HER 2阴性乳腺癌患者侵袭性较低和预后较好相关。FOXA 1可能有助于识别那些可能不需要辅助CT的患者。
Background Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer.Methods The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis.Results GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT.Conclusion GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.